Valneva (VLS)

11.065
+0.130(+1.19%)
  • Volume:
    207,792
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    10.660 - 11.135
  • Type:Equity
  • Market:France
  • ISIN:FR0004056851

VLS Overview

Prev. Close
10.935
Day's Range
10.66-11.135
Revenue
-
Open
10.9
52 wk Range
9.162-29.7
EPS
-0.72
Volume
207,792
Market Cap
1.19B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
808,510
P/E Ratio
-
Beta
0.61
1-Year Change
3.26%
Shares Outstanding
107,781,582
Next Earnings Date
Aug 11, 2022
What is your sentiment on Valneva?
or
Market is currently closed. Voting is open during market hours.

Valneva News

Valneva Analysis

Valneva Company Profile

Valneva Company Profile

Employees
762
Market
France

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyBuySellNeutral
Technical IndicatorsNeutralStrong BuyStrong BuyStrong SellSell
SummaryBuyStrong BuyStrong BuyStrong SellNeutral
  • 2 eme vague d elliott terminee? on passe a la 3 eme,y?
    0
    • 2€ soon
      1
      • Faire autant de pub pour une daube comme Sanofi alors que pas un mot n'a jamais été dit pour valneva
        0
        • direction 5 euros ... fini la fête .. Jonson aurait arrêté son vaccin et le reste vont suivre ..!
          3
          • Ha siktir len Aryoul
            0
        • 10€ soon
          4
          • target price 40€ according to société générale
            1
            • when you read this please ?
              0
          • target price 30€ according to investir
            0
            • ! Écrivesperons que ce ne soit pas un ETE avec 12 comme cible!! ez vo🤔s pensées sur Valneva
              0
              • English please.
                0
            • this is a salty beat joke.!
              0
              • will go up again today ? or not ? any opinion please ?
                0